» Articles » PMID: 12692073

Which 5-ASA?

Overview
Journal Gut
Specialty Gastroenterology
Date 2003 Apr 15
PMID 12692073
Authors
Affiliations
Soon will be listed here.
References
1.
Green J, Lobo A, HOLDSWORTH C, Leicester R, Gibson J, Kerr G . Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology. 1998; 114(1):15-22. DOI: 10.1016/s0016-5085(98)70627-4. View

2.
Kruis W, Schreiber S, Theuer D, Brandes J, Schutz E, Howaldt S . Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut. 2001; 49(6):783-9. PMC: 1728533. DOI: 10.1136/gut.49.6.783. View

3.
Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J . Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol. 1993; 88(8):1188-97. View

4.
Green J, Mansfield J, Gibson J, Kerr G, Thornton P . A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther. 2002; 16(1):61-8. DOI: 10.1046/j.1365-2036.2002.01150.x. View

5.
Pruitt R, Hanson J, Safdi M, Wruble L, Hardi R, Johanson J . Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol. 2002; 97(12):3078-86. DOI: 10.1111/j.1572-0241.2002.07103.x. View